IRONWOOD PHARMACEUTICALS, INC. Current Portion of Long-Term Debt
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Current Portion of Long-Term Debt of $120.70 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities
us-gaap:LongTermDebtCurrent · last filed 2022-05-05
- 2022-03-31: Long-term Debt, Current Maturities $120.70M.
- 2021-09-30: Long-term Debt, Current Maturities $120.70M.
- 2021-06-30: Long-term Debt, Current Maturities $120.70M.
| Period end | Long-term Debt, Current Maturities |
|---|---|
| 2022-03-31 | $120.70M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $120.70M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $120.70M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |